Recent studies have revealed that MHC class Ib (MHC Ib) molecules contribute to the host immune response by presenting conserved microbial antigens to T cells. H2-M3 (M3), for example, presents N- formylated bacterial peptides to CD8+ cytotoxic T cells. However, the function of most MHC Ib molecules in immunity against intracellular bacterial infection remains largely unknown. Using mice that lack both MHC class Ia (MHC Ia) and M3 (Kb-/-Db-/-M3-/- mice), we found that non-M3 MHC Ib molecules are involved in antigen presentation to CD8+ T cells during Mycobacterium tuberculosis (Mtb) infection, although their exact role and the relative contribution of different MHC Ib molecules is yet to be determined. Unlike MHC Ia- restricted T cells, MHC Ib-restricted CD8+ T cells can exhibit a pre-activated phenotype in na?ve animals and respond rapidly to infection. Recently, we found that thymic selecting cell type plays an important role in determining the phenotype of M3-restricted T cells;hematopoietic cell-selected M3-restricted T cells acquire a more activated phenotype and possess more potent effector functions than those selected on thymic epithelial cells. However, it is still unclear how selecting cell type influences the phenotype of the resulting CD8+ T cells. One molecule that may play a role in regulating development of a pre-activated phenotype is SAP (SLAM-associated protein), which is known to be involved in the development of certain innate T cells. This proposal seeks to investigate the molecular and cellular mechanisms involved in regulating the development and function of MHC Ib-restricted CD8+ T cells, and to determine what roles these T cells play during Mtb infection.
In Aim 1, we propose to determine whether SAP is required for hematopoietic cell- mediated selection of M3-restricted T cells and how SAP affects the effector functions of M3 and other MHC Ib-restricted CD8+ T cells.
In Aim 2, we propose to characterize the repertoire and functionality of non-M3, MHC Ib-restricted CD8+ T cells in the immune response to aerogenic Mtb infection through the generation of T cell lines from infected Kb-/-Db-/-M3-/- mice. We will further assess the protective role of these CTL lines using an adoptive transfer approach.
In Aim 3, we will focus on one MHC Ib molecule, Qa-1, as its human homolog HLA-E is known to present numerous Mtb peptides to CD8+ T cells, resulting in both cytotoxic and immunoregulatory activity. We propose to identify which HLA-E-binding Mtb peptides can also be presented by Qa-1 and examine the protective effect conferred by immunization with these peptides in Mtb infection. Further, we will characterize the immunoregulatory function of Qa-1 in anti-Mtb immunity, as well as the mechanisms responsible for this, using Qa-1-/- and Qa-1 mutant mice infected with Mtb. The results from our study will yield a better understanding of the developmental requirements, diversity and function of the MHC Ib-restricted immune response to Mtb, as well as potential new targets for Mtb vaccine development.

Public Health Relevance

The MHC class Ib molecules comprise the majority of the MHC class I family but their role in anti- microbial immunity is relatively unknown. This study proposes to utilize novel animal models to examine the developmental requirements, regulation, and function of various MHC class Ib-restricted T cells in host defense against Mycobacterium tuberculosis, the causative agent of tuberculosis. Such studies may lead to identification of new targets for T-cell based vaccines against mycobacterial infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI040310-17
Application #
8605490
Study Section
Immunity and Host Defense Study Section (IHD)
Program Officer
Lapham, Cheryl K
Project Start
1996-07-01
Project End
2017-01-31
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
17
Fiscal Year
2014
Total Cost
$386,250
Indirect Cost
$136,250
Name
Northwestern University at Chicago
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Bian, Yao; Shang, Shaobin; Siddiqui, Sarah et al. (2017) MHC Ib molecule Qa-1 presents Mycobacterium tuberculosis peptide antigens to CD8+ T cells and contributes to protection against infection. PLoS Pathog 13:e1006384
Zhao, Jie; Siddiqui, Sarah; Shang, Shaobin et al. (2015) Mycolic acid-specific T cells protect against Mycobacterium tuberculosis infection in a humanized transgenic mouse model. Elife 4:
Weng, Xiufang; Liao, Chia-Min; Bagchi, Sreya et al. (2014) The adaptor protein SAP regulates type II NKT-cell development, cytokine production, and cytotoxicity against lymphoma. Eur J Immunol 44:3646-57
Sena, Laura A; Li, Sha; Jairaman, Amit et al. (2013) Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity 38:225-36
Bediako, Yaw; Bian, Yao; Zhang, Hong et al. (2012) SAP is required for the development of innate phenotype in H2-M3--restricted Cd8(+) T cells. J Immunol 189:4787-96
Andrews, Daniel M; Sullivan, Lucy C; Baschuk, Nikola et al. (2012) Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells. Nat Immunol 13:1171-7
Cho, Hoonsik; Bediako, Yaw; Xu, Honglin et al. (2011) Positive selecting cell type determines the phenotype of MHC class Ib-restricted CD8+ T cells. Proc Natl Acad Sci U S A 108:13241-6
Cho, Hoonsik; Choi, Hak-Jong; Xu, Honglin et al. (2011) Nonconventional CD8+ T cell responses to Listeria infection in mice lacking MHC class Ia and H2-M3. J Immunol 186:489-98
Wang, T; Ahmed, E B; Chen, L et al. (2010) Infection with the intracellular bacterium, Listeria monocytogenes, overrides established tolerance in a mouse cardiac allograft model. Am J Transplant 10:1524-33
Felio, Kyrie; Nguyen, Hanh; Dascher, Christopher C et al. (2009) CD1-restricted adaptive immune responses to Mycobacteria in human group 1 CD1 transgenic mice. J Exp Med 206:2497-509

Showing the most recent 10 out of 13 publications